SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as retail investors rally behind its long-standing status as a reliable proof-of-work asset, with community members actively discussing a potential breakout fueled by its speed, institutional interest, and upcoming halving. While some traders express frustration over price stagnation compared to other assets, many are focused on accumulating the token as they anticipate a significant valuation shift.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro is gaining significant traction as a specialized play on Edge AI, with community sentiment driven by its ultra-low-power chip architecture and perceived potential for widespread adoption in wearables and smart devices. Investors are closely monitoring its growth trajectory and potential industry partnerships, focusing on the company's ability to capitalize on the shift of AI workloads from cloud data centers to local hardware endpoints.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors monitor its aggressive pivot from Bitcoin mining to AI data center infrastructure, specifically following the confirmation of AWS as a key tenant for its Stingray facility. The community is actively debating the stock's valuation and long-term potential, with many traders focused on technical support levels following recent volatility and large-scale note offerings intended to fund high-performance computing expansion.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is seeing strong bullish momentum driven by its integration into the Walmart Better Care Services platform and expanding insurance coverage for its BetterHelp division. The community is actively discussing a potential short squeeze, given the significant short interest and institutional accumulation, while long-term investors highlight the stock's value proposition as a global digital healthcare platform leveraging AI to scale virtual care.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on its pivotal role in U.S. critical mineral independence, specifically its progress in domestic rare earth processing at the White Mesa Mill. The community is actively discussing the company's $725M government loan commitment and its potential as a strategic national asset that provides essential materials for the defense and EV sectors, moving beyond traditional uranium mining.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is gaining traction as investors pivot toward infrastructure-oriented plays that can address the surge in power demand from AI and data centers. The community is actively debating the company's long-term value, with many highlighting its shift toward virtual power plants and storage solutions as a potential utility-like rerating catalyst despite persistent concerns over residential solar industry headwinds and regulatory uncertainty.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors weigh strong GAAP financials and aggressive share buyback programs against broader sector volatility surrounding potential federal rescheduling. Community sentiment is deeply divided, with bulls highlighting the company's best-in-class operations while bears express frustration over prolonged stagnation and the lack of a major exchange uplisting.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors grow increasingly optimistic about the upcoming phase 3 trial launch for its NSCLC program, a catalyst many believe will transform the company into a multi-asset oncology platform. The stock is seeing high social media engagement and institutional attention, with community members actively discussing the potential for a multibillion-dollar buyout given the company's progress toward a BLA submission and its novel approach to treating localized prostate cancer.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending as investors weigh significant insider accumulation and institutional buying from firms like Baker Bros against the upcoming Q3 Phase 2 clinical readout for the ABCL635 program. While community sentiment remains polarized between long-term supporters citing the company's platform and pipeline potential and skeptics frustrated by historical performance, the focus is squarely on the upcoming clinical data and partnership developments as the primary catalyst for valuation re-rating.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is drawing intense interest as market participants weigh persistent geopolitical volatility in the Middle East, specifically regarding shipping lanes in the Strait of Hormuz, against speculative news of potential ceasefire negotiations. The community is actively debating whether the current price action reflects long-term energy supply constraints and debt-reduction tailwinds for upstream producers or if short-term news headlines are creating artificial volatility that requires careful navigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCelleras antibody...

Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients...

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging  ABCELLERA BIOLG (ABCL) This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.53
Prev Close	$5.44
Open	$5.61
Dividend Yield	0.00%
50-Day Moving Average	$4.77
Beta	1.66
Avg. Volume	9.48M
PE Ratio	-11.53

52-Week High	$6.79
52-Week Low	$2.75
Market Capitalization	$1.69B
EPS (Annual)	-$0.4901
Price to Book	1.79
Revenue Per Employee	$133,679.71

ABCLAbCellera Biologics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABCL News